#United States #Pleasanton #Veeva #OpenEvidence #Open Vista

Veeva Partners with OpenEvidence for Clinical Trial Innovation

Veeva Systems, a prominent player in the life sciences sector, has recently announced a strategic partnership with OpenEvidence, the creator of a groundbreaking AI-driven clinical decision support tool. This collaboration aims to develop and market Open Vista, which is designed to enhance patient access to clinical trials and deepen the understanding of unmet medical needs, ultimately accelerating drug discovery and improving the adoption of existing approved medications.

OpenEvidence, led by CEO Daniel Nadler, is already making significant strides in the medical community. With over 40% of U.S. physicians actively utilizing its AI technology, the company focuses on distributing medical knowledge efficiently. Nadler emphasizes that by bridging the gap between peer-reviewed evidence and real-world medical practice, OpenEvidence enhances the transition of medical research from basic science to clinical application. For many patients suffering from severe diseases who have completed first and second-line treatments, clinical trials can often represent the most promising avenue for medical care.

The Collaboration's Potential

By partnering with Veeva, OpenEvidence gains the unique opportunity to leverage AI technology to connect physicians and patients with relevant clinical trials and innovative treatment options. Veeva's CEO Peter Gassner expressed enthusiasm for this collaboration, particularly as the life sciences industry enters an era dominated by AI. The combined strengths of Veeva and OpenEvidence are believed to create a bridge between pharmaceutical developers, patients, and healthcare professionals aiming to save lives.

The mission of Open Vista is slated to facilitate the rapid development of effective new therapies by life sciences companies, making it easier for more patients to participate in clinical trials. Furthermore, it strives to enhance understanding and uptake of existing medications in order to improve patient outcomes.

The first rollout of Open Vista is expected in 2026, marking a significant milestone in clinical support technology.

About Veeva Systems

Headquartered in Pleasanton, California, Veeva Systems specializes in cloud services tailored to the life sciences industry. The company provides software, data, and consulting solutions, addressing the needs of more than 1,500 customers, ranging from the largest biopharmaceutical companies to emerging biotech firms. As a Public Benefit Corporation, Veeva is dedicated to balancing the interests of all its stakeholders, including customers, employees, shareholders, and the industry as a whole.

For more information, visit Veeva's website.

About OpenEvidence

OpenEvidence is recognized as the fastest-growing clinical decision support platform in the U.S., widely utilized by clinicians across the country. It is trusted by numerous certified medical professionals for its reliable information, which is based and grounded on peer-reviewed medical literature. Established with the mission to organize and expand global medical knowledge, OpenEvidence is actively used in over 10,000 hospitals and medical centers in the U.S. and by more than 40% of American physicians.

Conclusion

The partnership between Veeva and OpenEvidence signifies an important advancement in the quest to improve patient care through enhanced access to clinical trials and innovations in treatment methodologies. As the world of medicine continues to evolve, such collaborations may prove vital in addressing the challenges faced within the healthcare landscape.